Imac Holdings, INC

IMAC Holdings, Inc. has turned over its Ignite Proteomics subsidiary and related assets to a collateral agent, satisfying senior secured notes and addressing a default.

IMAC Holdings, Inc. issued a secured promissory note with a principal of $175,000, receiving only $125,000 from a lender.

IMAC Holdings, Inc. has issued a secured promissory note with a principal amount of $222,600 for a purchase price of $159,000, maturing on January 31, 2026.

IMAC Holdings, Inc. issued a secured promissory note for $292,600, receiving $209,000, due January 31, 2026.

IMAC Holdings, Inc. has entered into a Securities Purchase Agreement to issue $7.5 million in senior secured notes, backed by substantially all company assets, maturing January 31, 2026.

IMAC Holdings, Inc. has issued a secured promissory note for $260,400, receiving $186,000, maturing on January 31, 2026.

IMAC Holdings reported a substantial increase in net loss and a worsening financial position, raising significant doubt about its ability to continue as a going concern.

IMAC Holdings reports a net loss of $2.1 million for Q2 2025, focusing on precision medicine in cancer treatment.

IMAC Holdings, Inc. reported a significant increase in net loss and cash burn for the first quarter of 2025, raising substantial doubt about its ability to continue as a going concern, despite a strategic pivot to precision cancer treatment.

IMAC Holdings, Inc. has filed an amended quarterly report for Q3 2024, restating previous financial statements due to preferred dividend accounting errors, revealing a significantly increased accumulated deficit and a substantial doubt about its ability to continue as a going concern.

IMAC Holdings, Inc. has filed an amended quarterly report for Q2 2024, restating prior financials due to preferred dividend accounting errors, while continuing its strategic shift to precision cancer medicine despite significant liquidity challenges and ongoing regulatory audits.

IMAC Holdings shifts focus to precision medicine in cancer treatment, reporting a net loss of $2.2 million for the third quarter of 2024, while discontinuing its previous clinic operations.

IMAC Holdings, Inc. has undergone a significant strategic shift, divesting its previous patient care operations to focus entirely on oncology proteomics, while simultaneously addressing a financial restatement and navigating a delisting from Nasdaq.

IMAC Holdings transitions to proteomic services, acquiring Theralink assets, while grappling with Nasdaq delisting due to Minimum Equity Rule non-compliance.

IMAC Holdings files an amended 10-K, restating its financials and detailing its strategic shift away from clinic operations towards a merger with Theralink Technologies.

IMAC Holdings, Inc. ceased operations at all outpatient medical clinics and BackSpace locations by the end of 2023, shifting focus to strategic alternatives.

Director Jorge Ruiz of IMAC Holdings, Inc. purchased 1 share of common stock at $2.69 on April 5, 2024, increasing his direct holdings to 141,230 shares.

Director Jorge Ruiz of IMAC Holdings, Inc. sold 5,000 shares of common stock at $3 per share on March 27, 2024.

Director Jorge Ruiz of IMAC Holdings, Inc. recently sold a portion of his common stock holdings, as indicated in a Form 4 filing with the SEC.

Director Jorge Ruiz of IMAC Holdings, Inc. reports acquiring 164,872 shares of common stock at $3.5797 per share and disposing of 16,487 shares at $2.4234 per share on March 22, 2024.

Director Jeffrey Busch received 3,333 shares of common stock as part of his 2024 board compensation, according to a recent SEC filing.

Director Michael D. Pruitt acquired 3,333 shares of IMAC Holdings common stock as part of his annual board compensation for 2024.

IMAC Holdings amended its bylaws to reduce the quorum requirement for stockholder meetings to one-third of outstanding voting shares, effective immediately and applicable retroactively to the upcoming Special Meeting.

IMAC Holdings issues a supplement to its proxy statement clarifying details regarding the potential issuance of shares related to its Series G Preferred Stock and Warrants.

IMAC Holdings is calling a special meeting of stockholders on March 26, 2025, to vote on proposals including potential stock issuance, increasing authorized shares, and a reverse stock split.

IMAC Holdings is holding a special meeting of stockholders to vote on proposals including the potential issuance of common stock related to Series G Preferred Stock and a committed equity financing, as well as an increase in authorized common stock and a reverse stock split.

IMAC Holdings, Inc. is holding its annual stockholder meeting on August 30, 2024, to vote on director elections, auditor ratification, executive compensation, and an amendment to the 2018 Incentive Compensation Plan.

IMAC Holdings intends to raise up to $60 million through an equity line of credit to support its proteomics business, focusing on oncology treatment decisions.

IMAC Holdings plans to potentially raise up to $60 million through an equity line of credit with Keystone Capital Partners, while navigating Nasdaq compliance challenges.

IMAC Holdings has filed an amendment to its registration statement for the potential resale of up to 35,007,025 shares of common stock by Keystone Capital Partners, LLC.

IMAC Holdings is seeking to raise capital through a public offering of common stock and warrants to support its strategic shift towards precision medicine with its Theralink technology.

Jorge Ruiz has reported a beneficial ownership of 13.03% of IMAC Holdings, Inc.'s common stock, holding 148,385 shares with sole voting and dispositive power, as disclosed in a recent Schedule 13G filing.

Jorge Ruiz has filed a Schedule 13G, disclosing a beneficial ownership of 14.48% of IMAC Holdings, Inc.'s common stock, with sole voting and dispositive power over the shares.